Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

Evolution of the neuraminidase gene of seasonal influenza A and B viruses in Thailand between 2010 and 2015.

Tewawong N, Vichiwattana P, Korkong S, Klinfueng S, Suntronwong N, Thongmee T, Theamboonlers A, Vongpunsawad S, Poovorawan Y.

PLoS One. 2017 Apr 14;12(4):e0175655. doi: 10.1371/journal.pone.0175655. eCollection 2017.

2.

Identification of influenza A nucleoprotein body domain residues essential for viral RNA expression expose antiviral target.

Davis AM, Ramirez J, Newcomb LL.

Virol J. 2017 Feb 7;14(1):22. doi: 10.1186/s12985-017-0694-8.

3.

Mutations Designed by Ensemble Defect to Misfold Conserved RNA Structures of Influenza A Segments 7 and 8 Affect Splicing and Attenuate Viral Replication in Cell Culture.

Jiang T, Nogales A, Baker SF, Martinez-Sobrido L, Turner DH.

PLoS One. 2016 Jun 7;11(6):e0156906. doi: 10.1371/journal.pone.0156906. eCollection 2016.

4.

How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation.

Waghmare A, Englund JA, Boeckh M.

Blood. 2016 Jun 2;127(22):2682-92. doi: 10.1182/blood-2016-01-634873. Epub 2016 Mar 11. Review.

5.

Clinical Implications of Antiviral Resistance in Influenza.

Li TC, Chan MC, Lee N.

Viruses. 2015 Sep 14;7(9):4929-44. doi: 10.3390/v7092850. Review.

6.

Understanding the cross-resistance of oseltamivir to H1N1 and H5N1 influenza A neuraminidase mutations using multidimensional computational analyses.

Singh A, Soliman ME.

Drug Des Devel Ther. 2015 Jul 31;9:4137-54. doi: 10.2147/DDDT.S81934. eCollection 2015.

7.

Mechanisms of action and efficacy of statins against influenza.

Mehrbod P, Omar AR, Hair-Bejo M, Haghani A, Ideris A.

Biomed Res Int. 2014;2014:872370. doi: 10.1155/2014/872370. Epub 2014 Nov 11. Review.

8.

Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies.

Chemaly RF, Shah DP, Boeckh MJ.

Clin Infect Dis. 2014 Nov 15;59 Suppl 5:S344-51. doi: 10.1093/cid/ciu623. Review.

9.

Emerging antiviral resistant strains of influenza A and the potential therapeutic targets within the viral ribonucleoprotein (vRNP) complex.

Davis AM, Chabolla BJ, Newcomb LL.

Virol J. 2014 Sep 16;11:167. doi: 10.1186/1743-422X-11-167. Review.

10.

Emerging and resistant infections.

Clancy CJ, Kalil AC, Fowler VG, Ghedin E, Kolls JK, Nguyen MH.

Ann Am Thorac Soc. 2014 Aug;11 Suppl 4:S193-200. doi: 10.1513/AnnalsATS.201402-069PL. Review.

11.

Evolution of oseltamivir resistance mutations in Influenza A(H1N1) and A(H3N2) viruses during selection in experimentally infected mice.

Pizzorno A, Abed Y, Plante PL, Carbonneau J, Baz M, Hamelin MÈ, Corbeil J, Boivin G.

Antimicrob Agents Chemother. 2014 Nov;58(11):6398-405. doi: 10.1128/AAC.02956-14. Epub 2014 Aug 11.

12.

Secondary structure of a conserved domain in an intron of influenza A M1 mRNA.

Jiang T, Kennedy SD, Moss WN, Kierzek E, Turner DH.

Biochemistry. 2014 Aug 19;53(32):5236-48. doi: 10.1021/bi500611j. Epub 2014 Aug 6.

13.

2D IR spectroscopy reveals the role of water in the binding of channel-blocking drugs to the influenza M2 channel.

Ghosh A, Wang J, Moroz YS, Korendovych IV, Zanni M, DeGrado WF, Gai F, Hochstrasser RM.

J Chem Phys. 2014 Jun 21;140(23):235105. doi: 10.1063/1.4881188.

14.
15.

Prevention of influenza by targeting host receptors using engineered proteins.

Connaris H, Govorkova EA, Ligertwood Y, Dutia BM, Yang L, Tauber S, Taylor MA, Alias N, Hagan R, Nash AA, Webster RG, Taylor GL.

Proc Natl Acad Sci U S A. 2014 Apr 29;111(17):6401-6. doi: 10.1073/pnas.1404205111. Epub 2014 Apr 14.

16.

Tannins from Hamamelis virginiana bark extract: characterization and improvement of the antiviral efficacy against influenza A virus and human papillomavirus.

Theisen LL, Erdelmeier CA, Spoden GA, Boukhallouk F, Sausy A, Florin L, Muller CP.

PLoS One. 2014 Jan 31;9(1):e88062. doi: 10.1371/journal.pone.0088062. eCollection 2014.

17.

Influenza treatment and prophylaxis with neuraminidase inhibitors: a review.

Kamali A, Holodniy M.

Infect Drug Resist. 2013 Nov 19;6:187-98. doi: 10.2147/IDR.S36601. eCollection 2013. Review.

18.

Impact of potential permissive neuraminidase mutations on viral fitness of the H275Y oseltamivir-resistant influenza A(H1N1)pdm09 virus in vitro, in mice and in ferrets.

Abed Y, Pizzorno A, Bouhy X, Rhéaume C, Boivin G.

J Virol. 2014 Feb;88(3):1652-8. doi: 10.1128/JVI.02681-13. Epub 2013 Nov 20.

19.

3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.

Rey-Carrizo M, Torres E, Ma C, Barniol-Xicota M, Wang J, Wu Y, Naesens L, DeGrado WF, Lamb RA, Pinto LH, Vázquez S.

J Med Chem. 2013 Nov 27;56(22):9265-74. doi: 10.1021/jm401340p. Epub 2013 Nov 15.

20.

Emergence of an oseltamivir-resistant influenza A/H3N2 virus in an elderly patient receiving a suboptimal dose of antiviral prophylaxis.

Roussy JF, Abed Y, Bouhy X, Boivin G.

J Clin Microbiol. 2013 Dec;51(12):4234-6. doi: 10.1128/JCM.02659-13. Epub 2013 Oct 2.

Supplemental Content

Support Center